Lagociclovir  (Synonyms: MIV-210)

Lagociclovir (FLG) is a nucleoside analogue that inhibits wild-type hepatitis B virus (HBV) replication in a human hepatoma cell line permanently expressing HBV^[1].

HBV^[1]

Lagociclovir (FLG) (6 days) shows inhibitory activity with IC₅₀s of 8 ± 3.8, 9 ± 2.5, 13 ± 3.4 and 15 ± 6.8 μM against 3TC-R HBV, wt HBV, PMEA-R HBV and 3TC+PMEA-R HBV, respectively in transiently transfected Huh7 cells^[1].
Lagociclovir (0-100 μM; 6 days) inhibits the replication of wild-type and drug-resistant mutants of HBV in transiently transfected Huh7 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

269.23

C₁₀H₁₂FN₅O₃

92562-88-4

O=C(N=C(N)N1)C2=C1N([C@@H]3O[C@H](CO)[C@@H](F)C3)C=N2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Jacquard AC, et al. In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine. Antimicrob Agents Chemother. 2006 Mar;50(3):955-61.  [Content Brief]